Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 9/20 | 0.64 |
| ▸ | HTR7 | P34969 | 8/20 | 0.64 |
| ▸ | HTR2A | P28223 | 6/20 | 0.64 |
| ▸ | HTR1A | P08908 | 5/20 | 0.64 |
| ▸ | DRD2 | P14416 | 5/20 | 0.64 |
| ▸ | HRH1 | P35367 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4808915 | 0.99 | HTR6 (0.63) | HTR6HTR7HTR2AHTR1ADRD2 | |
| SCHEMBL3559568 | 0.86 | HTR6 (0.71) | HTR6HTR7HTR2AHTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL2198927 | 0.85 | HTR6 (0.69) | HTR6HTR7HTR2AHTR1ADRD2 | |
| SCHEMBL15503471 | 0.85 | HTR6 (0.80) | HTR6HTR7HTR2AHTR1ADRD2 | |
| SCHEMBL2197288 | 0.85 | HTR6 (0.80) | HTR6HTR7HTR2AHTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL4807140 | 0.84 | HTR6 (0.78) | HTR6HTR7HTR2AHTR1ADRD2 | |
| SCHEMBL3561570 | 0.84 | HTR6 (0.67) | HTR6HTR7HTR2AHTR1ADRD2 | |
| SCHEMBL3556346 | 0.84 | HTR6 (0.67) | HTR6HTR7HTR2AHTR1ADRD2 | |
| SCHEMBL14400458 | 0.83 | HTR6 (0.82) | HTR6HTR7HTR2AHTR1ADRD2 | |
| SCHEMBL4813026 | 0.82 | HTR6 (0.67) | HTR6HTR7HTR2AHTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439244-B2 | Quinoline compounds and pharmeceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 2008-10-21 | — | — | US | claimed |
| JP-2007505075-A | — | — | 2007-03-08 | — | — | JP | claimed |
| US-20060287334-A1 | Quinoline compounds and pharmeceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 2006-12-21 | — | — | US | claimed |
| EP-1663980-A1 | QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 2006-06-07 | — | — | EP | claimed |
| WO-2005026125-A1 | QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 2005-03-24 | — | — | WO | claimed |
| US-7439244-B2 | Quinoline compounds and pharmeceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 2008-10-21 | — | — | US | disclosed |
| US-7439244-B2 | Quinoline compounds and pharmeceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 2008-10-21 | — | — | US | disclosed |
| WO-2005026125-A1 | QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287334-A1 | Quinoline compounds and pharmeceutical compositions containing them | ATP6V1B2, CNR2, CNR1 | HTR6 43/4885HTR7 39/4885HTR2A 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.